



## Curriculum Vitae

Personal information **Jonathan Bergman**

### Work experience

---

- Statistical assessor, Swedish Medical Products Agency, Sweden, Aug 2023 - Present
- Trainee, European Medicines Agency, The Netherlands, Oct 2022 - Jul 2023  
*Main activities: estimands, reviewing scientific advice letters*
- Project assistant, Umeå University, Sweden, Feb 2017 - Mar 2018  
*Main activities: osteoporosis research, pharmacoepidemiology*
- Intern, Umeå University, Sweden, Jun 2016 - Jan 2017  
*Main activities: osteoporosis research, pharmacoepidemiology*

### Education and training

---

- PhD in medical science, geriatric medicine, Umeå University, Sweden, Apr 2018 - Jun 2022  
*Subjects/skills: osteoporosis, clinical trials, pharmacoepidemiology, registry-based research, database management*
- Bachelor of science in governance and administration, statistics, Umeå University, Sweden, Sep 2012 - Jul 2016  
*Subjects/skills: law, economics, political science, statistics*

### Additional information

---

#### Publications

- Bergman J. *Benefits and harms of bisphosphonates: an observational study*. Umeå: Umeå university, 2022. (Dissertation.)
- Marcel B, Bergman J, Kiivipelto M, Nordström A, Nordström P. Excess mortality after COVID-19 in Swedish long-term care facilities. *J Am Med Dir Assoc* 2021; 22: 1574.
- Bergman J, Marcel B, Nordström A, Nordström P. Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: a nationwide study. *Eur J Epidemiol* 2021; 36: 287.
- Bergman J, Nordström A, Nordström P. Epidemiology of osteonecrosis among older adults in Sweden. *Osteoporos Int* 2019; 30: 965.
- Bergman J, Nordström A, Nordström P. Overestimation of the limitations of randomized controlled trials. *J Bone Miner Res* 2019; 34: 1767.
- Bergman J, Nordström A, Hommel A, et al. Bisphosphonates and mortality: confounding in observational studies? *Osteoporos Int* 2019; 30: 1973.
- Bergman J, Nordström A, Nordström P. Bisphosphonate use after clinical fracture and risk of new fracture. *Osteoporos Int* 2018; 29: 937.
- Bergman J, Nordström A, Nordström P. Alendronate use and the risk of nonvertebral fracture during glucocorticoid therapy: a retrospective cohort study. *J Clin Endocrinol Metab* 2018; 103: 306.

#### Projects

- Clinical trial statistician/coordinator, Fragility Fracture Trial (EudraCT: 2019-004766-17), Dec 2019 - Jun 2022

#### Memberships

- Board member, Swedish Society for Medical Statistics, Mar 2022 - Present

#### Other Relevant Information